Literature DB >> 16689023

Clinical and economic burden of psoriasis.

Elisabeth Hazard1, Spencer B Cherry, Deepa Lalla, J Michael Woolley, Helen Wilfehrt, Chiun-Fang Chiou.   

Abstract

In an effort to assess the burden associated with psoriasis, the MEDLINE database and bibliographies of articles published from 1975 through 2004 were searched, emphasizing patients with moderate-to-severe disease, to summarize the current understanding on various aspects of disease burden. The clinical burden of psoriasis is both well documented and significant. The disease is debilitating: Sufficient disease severity interferes with patients' work and day-to-day living. Perhaps even more damaging is the psychosocial toll psoriasis exacts on the afflicted. Numerous studies document the extent of mental and emotional anguish, features not often revealed through objective measures. Successful treatment must focus on improving a patient's quality of life as well as reducing the clinical features of psoriasis. The economic burden is also significant, though far fewer studies of the associated indirect costs have been published in the literature.

Entities:  

Mesh:

Year:  2006        PMID: 16689023

Source DB:  PubMed          Journal:  Manag Care Interface        ISSN: 1096-5645


  5 in total

1.  Combining mechanism-based prediction with patient-based profiling for psoriasis metabolomics biomarker discovery.

Authors:  QuanQiu Wang; Thomas S McCormick; Nicole L Ward; Kevin D Cooper; Ruzica Conic; Rong Xu
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  [Psoriasis und Psoriasis arthritis in childhood and adolescence. Overview and consensus statement of the 9th Wörlitz Expert Round Table Discussion 2006 for the Society for Child and Adolescent Rheumatology].

Authors:  M Sticherling; K Minden; R-M Küster; A Krause; M Borte
Journal:  Z Rheumatol       Date:  2007-07       Impact factor: 1.372

3.  Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.

Authors:  Giorgio L Colombo; Sergio Di Matteo; Chiara Martinotti; Steffen M Jugl; Praveen Gunda; Mariantonietta Naclerio; Giacomo M Bruno
Journal:  Clinicoecon Outcomes Res       Date:  2018-08-30

4.  Drug focus: adalimumab in the treatment of moderate to severe psoriasis.

Authors:  Gino A Vena; Nicoletta Cassano
Journal:  Biologics       Date:  2007-06

Review 5.  Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines.

Authors:  Josephine Mauskopf; Miny Samuel; Doreen McBride; Usha G Mallya; Steven R Feldman
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.